Description du projet
Comme pour la grossesse, un simple kit de test permet de détecter les cancers à un stade précoce
Le système gastro-intestinal humain abrite une communauté florissante de micro-organismes: le microbiote intestinal. Les évolutions de cet écosystème microscopique sont de plus en plus liées à plusieurs types de cancers. Étant donné le rôle critique de l’intestin dans la réabsorption des liquides et des nutriments dans le sang, les activités et les métabolites du microbiote intestinal affectent les tissus de manière systémique. Les biomarqueurs du cancer localisés dans l’intestin pourraient faciliter la détection très précoce des anomalies à l’origine des cancers et se traduire par un traitement précoce et une amélioration significative du pronostic. BiomStrip prévoit d’exploiter ce potentiel avec un système de test à domicile simple, similaire à un kit de test de grossesse. Ce kit de test pourrait bientôt mettre la médecine préventive entre les mains — et dans les intestins — des patients.
Objectif
Cancer is the second leading cause of death globally, causing 1 in 6 deaths. If cancer is diagnosed at early stage, it is highly likely to be treated successfully. Once it has grown and spread, therapy is vastly more difficult and costly, and survival rate drops rapidly. Screening is a vital healthcare element for early detection but suffers from burdens of cost, capacity, compliance, and detection sensitivity problems.
BiomStrip introduces a pioneering screening solution that can carry out cancer screening in the fashion of the common pregnancy tests. Building on our recent breakthrough results in biomarker validation granting TRL6 stage, we have designed a diagnostic device that is low-cost, non-invasive, accurate, can be handled by consumer, and bought over-the counter. The diagnostic method is based on detecting dysbiosis of gut microbial flora, a highly sensitive indicator of pathophysiological processes able to selectively show disease onset at super-early stage, even before histological changes are observable. The method is ultimately able to detect most cancer types and even other diseases, making it a future platform technology.
For highest scalability, fastest time-to-market, explosive growth, low resource-intensity, and minimised risk and overheads, we will license production and commercialisation to established multinational companies, keeping our focus as high-tech SME. Breast cancer will be our market entry point and other diseases will be covered subsequently form own resources.
To engineer this Workplan, a feasibility study will assess entry use cases and their markets, analyse business model and partnership options, and evaluate IPR strategies in a Strategic Business Plan.
The disruptive approach offers to transform cancer screening from top-down to bottom-up: empowering patients, gradually alleviating healthcare systems large effort and sums spent on preventive cancer diagnostics, and drastically improving therapeutical effectiveness.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
4032 DEBRECEN
Hongrie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.